// Wait for DOM to be fully loaded document.addEventListener(‘DOMContentLoaded’, function() { // Initialize slider value display const performanceSlider = document.getElementById(‘performanceStatus’); const performanceValue = document.getElementById(‘performanceStatusValue’); performanceSlider.addEventListener(‘input’, function() { performanceValue.textContent = this.value + ‘%’; }); // Calculate button click handler document.getElementById(‘calculateBtn’).addEventListener(‘click’, calculateRisk); // Reset button click handler document.getElementById(‘resetBtn’).addEventListener(‘click’, function() { document.getElementById(‘resultsContainer’).style.display = ‘none’; document.getElementById(‘neuroblastomaForm’).reset(); performanceValue.textContent = ‘100%’; }); // PDF generation document.getElementById(‘generatePdf’).addEventListener(‘click’, generatePdf); // Social sharing buttons setupSocialSharing(); }); function calculateRisk() { // Validate required fields if (!validateForm()) { return; } // Calculate score based on various factors let score = 0; // Age factor (higher risk for 18-60 months) const age = parseInt(document.getElementById(‘age’).value); if (age = 12 && age = 18 && age 10) score += 15; else if (tumorSize > 5) score += 10; // IDRFs const idrfs = document.querySelectorAll(‘input[name=”imageDefinedFactors”]:checked’); score += idrfs.length * 5; // Serum markers const ferritin = parseInt(document.getElementById(‘ferritin’).value) || 0; if (ferritin > 150) score += 5; if (ferritin > 300) score += 5; const ldh = parseInt(document.getElementById(‘ldh’).value) || 0; if (ldh > 750) score += 5; if (ldh > 1500) score += 5; // Treatment response const treatmentResponse = document.getElementById(‘treatmentResponse’).value; if (treatmentResponse === ‘progressive’) score += 25; else if (treatmentResponse === ‘stable’) score += 15; else if (treatmentResponse === ‘mixed’) score += 10; else if (treatmentResponse === ‘partial’) score += 5; // Cap the score at 100 score = Math.min(score, 100); // Display results displayResults(score); } function validateForm() { let isValid = true; const requiredFields = [‘patientName’, ‘age’, ‘inssStage’, ‘mycnStatus’, ‘histology’]; requiredFields.forEach(fieldId => { const field = document.getElementById(fieldId); if (!field.value) { isValid = false; field.style.borderColor = ‘#e74c3c’; setTimeout(() => { field.style.borderColor = ‘#ddd’; }, 2000); } }); if (!isValid) { alert(‘Please fill in all required fields.’); } return isValid; } function displayResults(score) { // Show results container document.getElementById(‘resultsContainer’).style.display = ‘block’; // Set the score document.getElementById(‘finalScore’).textContent = score; // Position the risk indicator const riskIndicator = document.getElementById(‘riskIndicator’); riskIndicator.style.left = `${score}%`; // Set interpretation text const interpretationText = document.getElementById(‘interpretationText’); let interpretation = ”; let riskLevel = ”; if (score = 30 && score < 60) { riskLevel = 'Intermediate Risk'; interpretation = `The calculated risk score of ${score} suggests an intermediate-risk neuroblastoma. These patients may require more aggressive therapy than low-risk patients but still have favorable outcomes with 5-year survival rates of approximately 85-90%.`; } else { riskLevel = 'High Risk'; interpretation = `The calculated risk score of ${score} indicates a high-risk neuroblastoma profile. These patients have aggressive disease biology and typically require intensive multimodal therapy. Despite aggressive treatment, 5-year survival rates remain around 50%.`; } interpretationText.textContent = interpretation; // Set recommendations based on risk level const recommendationsList = document.getElementById('recommendationsList'); recommendationsList.innerHTML = ''; if (riskLevel === 'Low Risk') { addRecommendation('Surgical resection alone may be sufficient for localized tumors'); addRecommendation('Consider observation for stage 4S patients with favorable biology'); addRecommendation('Minimal or no chemotherapy required'); addRecommendation('Regular follow-up with imaging and tumor marker monitoring'); } else if (riskLevel === 'Intermediate Risk') { addRecommendation('Moderate-dose chemotherapy (4-8 cycles)'); addRecommendation('Surgical resection after initial chemotherapy'); addRecommendation('Consider local radiation therapy for residual disease'); addRecommendation('Close monitoring for relapse with regular imaging and lab tests'); } else { addRecommendation('Intensive induction chemotherapy (high-dose regimens)'); addRecommendation('Consider tandem high-dose chemotherapy with stem cell rescue'); addRecommendation('Surgical resection of primary tumor when feasible'); addRecommendation('Radiation therapy to primary site and persistent metastatic sites'); addRecommendation('Immunotherapy (anti-GD2 antibodies) as maintenance therapy'); addRecommendation('Consider clinical trials for novel therapies'); addRecommendation('Aggressive supportive care for treatment-related toxicities'); } // Create patient summary createPatientSummary(score, riskLevel); // Scroll to results document.getElementById('resultsContainer').scrollIntoView({ behavior: 'smooth' }); } function addRecommendation(text) { const li = document.createElement('li'); li.textContent = text; document.getElementById('recommendationsList').appendChild(li); } function createPatientSummary(score, riskLevel) { const summaryDiv = document.getElementById('patientSummary'); summaryDiv.innerHTML = ''; const name = document.getElementById('patientName').value || 'Not provided'; const age = document.getElementById('age').value || 'Unknown'; const gender = document.querySelector('input[name="gender"]:checked').value; const stage = document.getElementById('inssStage').value; const mycn = document.getElementById('mycnStatus').value; const histology = document.getElementById('histology').value; const now = new Date(); const dateTimeString = now.toLocaleString(); const summaryHTML = `

Patient Summary

Name: ${name}

Age: ${age} months

Gender: ${gender.charAt(0).toUpperCase() + gender.slice(1)}

INSS Stage: ${stage}

MYCN Status: ${mycn}

Histology: ${histology}

Risk Category: ${riskLevel}

Assessment Date: ${dateTimeString}

`; summaryDiv.innerHTML = summaryHTML; } function setupSocialSharing() { const patientName = document.getElementById(‘patientName’).value || ‘a patient’; const score = document.getElementById(‘finalScore’).textContent || ‘0’; const shareText = `Neuroblastoma risk assessment for ${patientName}: Risk score of ${score}. Check out this comprehensive calculator at DoseWay.com`; const shareUrl = ‘https://doseway.com/neuroblastoma-calculator’; document.getElementById(‘shareFacebook’).addEventListener(‘click’, function(e) { e.preventDefault(); window.open(`https://www.facebook.com/sharer/sharer.php?u=${encodeURIComponent(shareUrl)}&quote=${encodeURIComponent(shareText)}`, ‘facebook-share-dialog’, ‘width=800,height=600’); }); document.getElementById(‘shareTwitter’).addEventListener(‘click’, function(e) { e.preventDefault(); window.open(`https://twitter.com/intent/tweet?text=${encodeURIComponent(shareText)}&url=${encodeURIComponent(shareUrl)}`, ‘twitter-share-dialog’, ‘width=800,height=600’); }); document.getElementById(‘shareLinkedIn’).addEventListener(‘click’, function(e) { e.preventDefault(); window.open(`https://www.linkedin.com/shareArticle?mini=true&url=${encodeURIComponent(shareUrl)}&title=Neuroblastoma%20Risk%20Assessment&summary=${encodeURIComponent(shareText)}`, ‘linkedin-share-dialog’, ‘width=800,height=600’); }); document.getElementById(‘shareWhatsApp’).addEventListener(‘click’, function(e) { e.preventDefault(); window.open(`https://wa.me/?text=${encodeURIComponent(shareText + ‘ ‘ + shareUrl)}`, ‘whatsapp-share-dialog’, ‘width=800,height=600’); }); } function generatePdf() { const { jsPDF } = window.jspdf; const doc = new jsPDF(); // Add header doc.setFontSize(18); doc.setTextColor(40, 53, 80); doc.text(‘Childhood Neuroblastoma Risk Assessment Report’, 105, 20, { align: ‘center’ }); doc.setFontSize(10); doc.setTextColor(100); doc.text(‘Generated by DoseWay.com | support@doseway.com | WhatsApp: +92318-6144650’, 105, 28, { align: ‘center’ }); // Add patient summary doc.setFontSize(12); doc.setTextColor(0); const patientSummary = document.getElementById(‘patientSummary’).textContent; const summaryLines = doc.splitTextToSize(patientSummary, 180); doc.text(summaryLines, 15, 40); // Add risk score doc.setFontSize(14); doc.setTextColor(40, 53, 80); doc.text(‘Risk Score:’, 15, 80); doc.setFontSize(24); doc.setTextColor(231, 76, 60); doc.text(document.getElementById(‘finalScore’).textContent, 40, 90); // Add interpretation doc.setFontSize(12); doc.setTextColor(0); const interpretation = document.getElementById(‘interpretationText’).textContent; const interpretationLines = doc.splitTextToSize(interpretation, 180); doc.text(interpretationLines, 15, 110); // Add recommendations doc.setFontSize(14); doc.setTextColor(40, 53, 80); doc.text(‘Clinical Recommendations:’, 15, 140); doc.setFontSize(12); doc.setTextColor(0); const recommendations = document.getElementById(‘recommendationsList’).querySelectorAll(‘li’); let yPosition = 150; recommendations.forEach(rec => { const lines = doc.splitTextToSize(rec.textContent, 180); doc.text(lines, 20, yPosition); yPosition += lines.length * 7; }); // Add footer doc.setFontSize(10); doc.setTextColor(100); doc.text(‘Page 1 of 1’, 105, 285, { align: ‘center’ }); doc.text(‘Confidential medical report – For clinical use only’, 105, 290, { align: ‘center’ }); // Save the PDF const patientName = document.getElementById(‘patientName’).value || ‘neuroblastoma-patient’; doc.save(`Neuroblastoma-Risk-Assessment-${patientName}.pdf`); }

Try More Free Tools:

• Try Our Neuroblastoma Risk Stratification Tool
• Try Our Do I Have Mesothelioma? Free Quiz For Early Diagnosis
• Try Our Mesothelioma Risk Calculator

Childhood Neuroblastoma Risk Calculator

Childhood Neuroblastoma: Risk Factors & Prognosis

Neuroblastoma is one of the most common extracranial solid tumors in children, accounting for 6-10% of all pediatric cancers. It arises from immature nerve cells (neuroblasts) and primarily affects infants and young children, with 90% of cases diagnosed before age 5.

This aggressive cancer varies widely in behavior—some tumors spontaneously regress, while others metastasize rapidly. To help clinicians and parents assess risk, we’ve developed a comprehensive Childhood Neuroblastoma Risk Calculator that evaluates tumor biology, staging, and clinical factors to predict prognosis and guide treatment decisions.

Key Factors in Childhood Neuroblastoma Risk Calculator

Our calculator evaluates multiple semantic terms and clinical parameters critical in neuroblastoma prognosis:

1. Patient Demographics

• Age at Diagnosis (Infants <18 months have better outcomes)
• Gender (Slightly more common in males)
• Ethnicity (Some genetic predispositions exist)

2. Tumor Characteristics

• Primary Tumor Site (Adrenal gland vs. sympathetic ganglia)
• Tumor Size (Larger tumors indicate higher risk)
• INSS Stage (International Neuroblastoma Staging System)
• Image-Defined Risk Factors (IDRFs) (Surgical resectability)

3. Biological Markers (Critical for Risk Stratification)

• MYCN Amplification (Strong predictor of aggressive disease)
• DNA Ploidy (Hyperdiploidy favors better prognosis)
• Histology (Schwannian stroma-rich vs. stroma-poor)
• Chromosomal Aberrations (1p/11q deletions worsen prognosis)

4. Serum Markers & Treatment Response

• Serum Ferritin & LDH (Higher levels indicate poor prognosis)
• Neuron-Specific Enolase (NSE) (Tumor burden marker)
• Response to Chemotherapy/Surgery (Complete vs. partial response)

How the Childhood Neuroblastoma Risk Calculator Works

Our tool calculates a risk score (0-100) based on:

✅ Low Risk (Score <30) – Excellent prognosis with >95% 5-year survival; may require surgery alone.
✅ Intermediate Risk (Score 30-59) – 85-90% survival; needs chemotherapy + surgery.
✅ High Risk (Score ≥60) – Poor prognosis (~50% survival); requires intensive chemo, radiation, immunotherapy, and stem cell transplant.

Example Calculation:

Factor	Points
Age: 24 months	+20
Stage 4	+40
MYCN Amplified	+35
Unfavorable Histology	+20
Total Score	115 (Capped at 100 – High Risk)

Interpreting Your Results

After entering data, the calculator provides:

📊 Risk Meter (Color-Coded) – Visual indicator of low (green), intermediate (yellow), or high (red) risk.
📝 Personalized Recommendations – Treatment options based on risk category.
📑 Downloadable PDF Report – For medical records or specialist consultations.

Why Use This Neuroblastoma Risk Assessment Tool?

🔹 Evidence-Based Scoring – Aligns with COG (Children’s Oncology Group) and INRG (International Neuroblastoma Risk Group) guidelines.
🔹 Helps Guide Treatment Decisions – Identifies whether minimal therapy or aggressive intervention is needed.
🔹 Improves Prognostic Accuracy – Combines clinical + biological factors for better risk prediction.

Final Thoughts

Early risk assessment is critical in neuroblastoma management. Our free Childhood Neuroblastoma Risk Calculator helps parents and oncologists evaluate prognosis and make informed treatment choices.

📥 Try the calculator now and download your personalized report!

FAQs